

# GRK1,4,7 phosphorylate MII to p-MII

Jassal, B., Makino, C.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of [Creative Commons Attribution 4.0 International \(CC BY 4.0\) License](#). For more information see our [license](#).

04/05/2024

## Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

## Literature references

- Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics*, 18, 142. [↗](#)
- Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics*, 33, 3461-3467. [↗](#)
- Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res*, 46, D649-D655. [↗](#)
- Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph database: Efficient access to complex pathway data. *PLoS computational biology*, 14, e1005968. [↗](#)

Reactome database release: 88


This document contains 1 reaction ([see Table of Contents](#))

## GRK1,4,7 phosphorylate MII to p-MII ↗

**Stable identifier:** R-HSA-2581474

**Type:** transition

**Compartments:** cytosol, photoreceptor disc membrane



Activated rhodopsin (MII aka R\*) must be deactivated to terminate the single photon response. Deactivation begins during the rising phase of the single photon response after MII binds rhodopsin kinase (GRK1), a serine/threonine protein kinase (Khani et al. 1996). GRK1 is activated by MII whereupon it phosphorylates MII at multiple serine and threonine sites on its C terminus. There are six serine and threonine residues that can be phosphorylated. Increasing phosphorylation progressively reduces the rate at which MII can activate transducin but full quenching requires the binding of arrestin (S-antigen or SAG, Yamaki et al. 1988) which binds to and sterically caps MII (Burns & Pugh 2010, Korenbrot 2012). GRK4- $\alpha$  (isoform 1) and GRK7 are also able to phosphorylate rhodopsin thereby deactivating it (Premont et al. 1996, Chen et al. 2001, Horner et al. 2005, Osawa et al. 2008).

A substantial fraction of rhodopsin kinase (GRK1) is bound to recoverin (RCVRN) in darkness, when internal  $\text{Ca}^{2+}$  levels are high. RCVRN is an EF-hand protein (Murakami et al. 1992) that functions as a myristoyl switch. With  $\text{Ca}^{2+}$  bound, the myristoyl group is exposed to attach RCVRN to the membrane. When  $\text{Ca}^{2+}$  levels drop with light exposure,  $\text{Ca}^{2+}$  dissociates from RCVRN and GRK1 is released. Higher levels of free GRK1 accelerate the phosphorylation and shutoff of photoexcited rhodopsin (MII).

Certain mutations in GRK1 cause Oguchi type 2 disease, a rare, recessive form of congenital stationary night blindness (<https://sph.uth.edu/retnet/>).

### Literature references

- Chen, YJ., Chen, CK., Frederick, JM., Huang, W., Zhang, K., Zhang, H. et al. (2001). Characterization of human GRK7 as a potential cone opsin kinase. *Mol. Vis.*, 7, 305-13. ↗
- Premont, RT., MacDonald, ME., Lefkowitz, RJ., Pitcher, JA., Stoffel, RH., Inglese, J. et al. (1996). Characterization of the G protein-coupled receptor kinase GRK4. Identification of four splice variants. *J. Biol. Chem.*, 271, 6403-10. ↗
- Korenbrot, JI. (2012). Speed, sensitivity, and stability of the light response in rod and cone photoreceptors: facts and models. *Prog Retin Eye Res*, 31, 442-66. ↗
- Pugh, EN., Burns, ME. (2010). Lessons from photoreceptors: turning off G-protein signaling in living cells. *Physiology (Bethesda)*, 25, 72-84. ↗
- Osawa, S., Schaller, MD., Weiss, ER., Horner, TJ. (2005). Phosphorylation of GRK1 and GRK7 by cAMP-dependent protein kinase attenuates their enzymatic activities. *J. Biol. Chem.*, 280, 28241-50. ↗

**Editions**

2012-11-13	Authored, Edited	Jassal, B.
2013-04-11	Reviewed	Makino, C.
2015-07-17	Revised	Jassal, B.